Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer save search
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
THER | $0.0009 62.5% 200K
|
n/a
|
| O: -80.0%
H: 400.0%
C: 300.0%
theralink health care collaboration cancer
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.78 -2.2% 370K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Published: 2022-07-26 (Crawled : 13:20) - biospace.com/
QBIO | $0.0002 100.0% 1.1K
|
Professional, Scientific, and T...
|
| O: 0.25%
H: 200.0%
C: 200.0%
drug candidate research liver pre-clinical therapy cancer publication
Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Published: 2021-12-28 (Crawled : 22:00) - biospace.com/
TSOI | $0.0007 0.0% 23M
|
Manufacturing
|
| O: -1.44%
H: 139.02%
C: 138.54%
covid-19 treatment patent covid cancer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
Published: 2023-02-07 (Crawled : 18:00) - globenewswire.com
LIXT | $3.56 10.56% 8.5K
|
Health Technology
|
| O: -1.33%
H: 237.5%
C: 136.25%
lb-100 pre-clinical cancer wee1 kinase stimulates the signals modest toxicity
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
Published: 2022-10-26 (Crawled : 14:00) - biospace.com/
EPIX | $6.53 2.03% 7.3K
|
Health Technology
|
| O: 19.19%
H: 148.78%
C: 135.12%
epi-7386 candidate results cancer study prostate cancer phase 1
Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer
Published: 2022-03-02 (Crawled : 17:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 1.79%
H: 128.07%
C: 110.53%
biopharma technology cel stem cell cancer
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ | $0.452 -1.72% 65K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
LUDG | $0.29 8.1K
|
n/a
|
| O: -49.15%
H: 92.0%
C: 92.0%
mrna bladder cancer study
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Published: 2021-03-08 (Crawled : 12:00) - biospace.com/
GLSI | $13.04 -0.76% 1.3K
|
Health Technology
|
| O: 0.04%
H: 130.25%
C: 61.67%
cancer breast cancer trial
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
Published: 2022-04-12 (Crawled : 14:20) - globenewswire.com
QLGN | $0.296 -6.03% 21K
|
Health Technology
|
| O: -4.43%
H: 160.94%
C: 59.11%
qn-302 research conference therapeutics cancer
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
Published: 2023-11-09 (Crawled : 13:30) - biospace.com/
KRBP | $2.64 360
|
Health Technology
|
| O: 3.96%
H: 53.85%
C: 53.85%
cancer biopharma trial
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office
Published: 2022-03-22 (Crawled : 14:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 14.48%
H: 104.22%
C: 50.6%
biopharma patent cancer
Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
BDTX | $4.91 -2.0% 130K
|
Health Technology
|
| O: 126.63%
H: 64.27%
C: 48.2%
bdtx-1535 lung cancer cell therapeutics
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.23 1.44% 84K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
crdf-004 first cancer trial
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
KRBP | $2.64 360
|
Health Technology
|
| O: -3.52%
H: 111.44%
C: 40.92%
cancer biopharma trial agreement
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Published: 2023-05-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.9 15.54% 460K
|
Health Technology
|
| O: 16.98%
H: 109.68%
C: 40.86%
lung cancer cell
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Published: 2024-01-25 (Crawled : 13:30) - globenewswire.com
PCSA | $1.6 7.1K
|
Producer Manufacturing
|
| O: 78.05%
H: 61.92%
C: 39.73%
cancer pharmaceuticals advanced
Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
Published: 2023-03-23 (Crawled : 13:00) - jaguarhealth.gcs-web.com
JAGX | News | $0.1701 1.25% 20M
|
Health Technology
|
| O: 0.19%
H: 51.57%
C: 39.25%
cancer kelly
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.